Vicarious Surgical Inc. announced its financial results for the first quarter ended March 31, 2025, on May 12, 2025, reporting a net loss of $(15,394) thousand, an improvement from $(17,001) thousand in the prior year period.
As of March 31, 2025, the company held $37,362 thousand in cash, cash equivalents, and short-term investments.
CEO Adam Sachs stated that the company is 'just a few quarters away from our biggest milestone yet - our first clinical patients' and that '2025 will be the year Vicarious Surgical evolves into a clinical-stage company.'
The company's investor presentation confirmed that first human use of the Version 1.0 System is planned for late 2025, with an anticipated FDA De Novo submission in late 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.